Monthly Prescribing Reference

Nipocalimab Designated Breakthrough Tx for Hemolytic Disease of the Fetus and Newborn

Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...
Healio

Extending antigen-matching protocols lowers odds for hemolytic disease of fetus, newborn

Please provide your email address to receive an email when new articles are posted on . Alloimmunization rates were 6.2% for women matched to ABO and Rhesus D and 1.9% for women also matched for c, E ...
Nasdaq

Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of ...

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine ...
Seeking Alpha

Johnson & Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and ...

Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to ...
Medscape

What's New in the New Jaundice Guidelines?

More than 15 years in the making, the revised AAP Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation was released in 2022. A key ...